Sorin is now LivaNova. Learn more here

Kora 100

Catalogue: Outside USA

20_det_kora100_C_v1.jpg

Kora 100 is the world’s smallest dual-chamber pacemaker1 implanted with Beflex leads and the market leader in reliability2

Featuring:

  • Automatic MRI Mode
  • Sleep Apnea Monitoring (SAM)
  • SafeR

Kora 100 technology provides the ideal combination of small size1, longevity3, and high performance2: 12 years longevity in only 8cc.

REFERENCES

  1. REPLY DR Competitive Summary, Sorin Group, ULS4222C, October 2013.
  2. Sorin Group Product Performance Report, May 2014.
  3. KORA 100 DR with typical conditions using SafeR: 50% A pacing, 5% V pacing, SAM ON, 60 min-1, 2.5V, 0.35ms, 750 ohms, EGM & Diagnostics ON, Rate response ON, Sensors ON. KORA 100 SR, 11.4 years of longevity in 7.5cc only with conditions: 100% V pacing, SAM ON, 60 min-1, 2.5V, 0.35ms, 750 ohms, EGM & Diagnostics on, Rate response on, Sensors ON.

This product is not available for sale or distribution in the USA. For further information on product availability, please contact your local representative

Features

Automatic MRI Mode

Limited time in asynchronous mode1,2

  • Switches automatically to asynchronous mode when detecting a strong magnetic field

One flexible visit3

  • Set MRI mode to Auto
  • Select the time window for the detection of a strong magnetic field (up to 48h)

Automatic switch to normal configuration3

  • Switches back 5 minutes after the patient is removed from the strong magnetic field

Proven lead technology4

  • Beflex RF45D and RF46D

 


Sleep apnea monitoring

Our Sleep apnea monitoring algorithm (SAM) measures respiration pauses and reductions.

  • Uses an MV sensor
  • Provides reliable, automatic screening to detect severe sleep apnea with high specificity (85%) and high sensitivity (89%)5
  • Correlated with gold standard apnea-hypopnea index5*
  • Designed to monitor the evolution of sleep apnea

 Sleep apnea monitoring is available in Kora 100 SR and DR.

*Apnea/hypopnea index = number of events/number of hours of sleep


**Depending on the patient profile and/or other symptoms, the physician may engage in dialogue with the patient and include a neurologist or a sleep specialist, as appropriate.


***RDI = number of ventilation pauses reductions/number of hours of monitoring

 


Intelligent management of AV conduction

ESC guidelines underline the importance of minimizing unnecessary ventricular pacing6

SafeR

  • Nearly eliminates ventricular pacing7
  • Adds 2 years of device longevity8
  • Manages all AV blocks9

SafeR was recently shown to be as safe and effective in AVB patients as in SND patients9

REferences

  1. Irnich W, Weiler G. The problems associated with asynchronous pacing stimulation. Rechtsmedizin 2009; 19:152–6.
  2. Nowak B et al. Safety of Asynchronous Ventricular Pacemaker Stimulation. Statement of the Working Group CardiacPacemakers of the German Cardiac Society 2005; 130:997-1001.
  3. SORIN MRI Solutions implant manual (U201) available at www.sorinmanuals.com
  4. Sorin Group Product Performance Report, May 2014.
  5. Defaye P, de la Cruz I, Martí-Almor J et al. A pacemaker transthoracic impedance sensor with an advanced algorithm to identify severe sleep apnea: The DREAM European study. Heart Rhythm 2014;11:842-8.
  6. European Society of Cardiology. Guidelines on cardiac pacing and cardiac resynchronization therapy. Magnetic resonance imaging in patients with implanted cardiac devices 2013.
  7. Davy JM, Hoffmann E, Frey A et al. Near elimination of ventricular pacing in SafeR mode compared to DDD modes: a randomized study of 422 patients. Pacing Clin Electrophysiol 2012; 35:392-402.
  8. Benkemoun H, Sacrez J, Lagrange P et al. Optimizing pacemaker longevity with pacing mode and settings programming: results from a pacemaker multicenter registry. Pacing Clin Electrophysiol 2012; 35:403-408.
  9. M. Stockburger, S. Boveda, P. Defaye, J. Moreno on behalf of the ANSWER Investigators. Evaluation of the SafeR Mode in patients with a dual chamber pacemaker indication (ANSWER): Long-term clinical outcome results of the ANSWER trial. European Heart Journal.2014 September.

 

 

Evidence

The ideal combination of small size1, longevity2 and performance3: 12 years longevity in only 8cc.

Kora 100 is built upon the Reply platform3


 

References

  1. REPLY DR Competitive Summary, Sorin Group, ULS4222C, October 2013.
  2. KORA 100 DR with typical conditions using SafeR: 50% A pacing, 5% V pacing, SAM ON, 60 min-1, 2.5V, 0.35ms, 750 ohms, EGM & Diagnostics ON, Rate response ON, Sensors ON. KORA 100 SR, 11.4 years of longevity in 7.5cc only with conditions: 100% V pacing, SAM ON, 60 min-1, 2.5V, 0.35ms, 750 ohms, EGM & Diagnostics on, Rate response on, Sensors ON.Sorin Group
  3. Product Performance Report, May 2014.

This product may not be for sale in your country or your area. For further information on product availability, please contact your local representative

Version unknown | Revision 110938 | Status unstable | SessionId 2A4E80732AFC4343DCD7E790D9B8DA4D.jvm0